Changes in Hong Kong stocks | Pharmaceutical stocks generally fell, Keli Pharmaceutical-B (01672) fell more than 11%, Shengnuo Pharmaceutical-B (02257) fell more than 8%

The Zhitong Finance App learned that pharmaceutical stocks generally declined. As of press release, Goli Pharmaceutical-B (01672) fell 11.02% to HK$12.92; Shengnuo Pharmaceutical-B (02257) fell 8.27% to HK$8.32; Hebo Pharmaceutical-B (02142) fell 7.29% to HK$12.46; Rongchang Biotech (09995) fell 4.87% to HK$75.15.

According to the news, the Haitong International Research Report pointed out that the pharmaceutical sector is recovering, and funding is under pressure in the short term; it is optimistic about long-term opportunities in the innovative drug industry chain. The overall performance of the Hong Kong stock pharmaceutical sector was weak last week. The bank believes that it is mainly affected by seasonal factors such as year-end settlement of capital going south. Liquidity in the Hong Kong stock pharmaceutical sector has weakened, and the Hong Kong Stock Connect shareholding ratio of leading pharmaceutical stocks continues to decline, such as Cinda Biotech and China Biopharmaceuticals. The bank has long been optimistic about leading Internet healthcare and CXO/research services with strong performance, as well as leading Biotech and pharmaceutical companies that have achieved foreign cooperation licenses, are progressing smoothly in overseas clinical trials, and have strong fundamentals.